ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GSK Gsk Plc

1,599.00
15.50 (0.98%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  15.50 0.98% 1,599.00 1,599.50 1,600.50 1,600.00 1,575.00 1,579.50 5,149,016 16:35:14
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.37 65.87B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,583.50p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £65.87 billion. Gsk has a price to earnings ratio (PE ratio) of 13.37.

Gsk Share Discussion Threads

Showing 16651 to 16672 of 33100 messages
Chat Pages: Latest  676  675  674  673  672  671  670  669  668  667  666  665  Older
DateSubjectAuthorDiscuss
12/2/2018
13:10
Not on the hook at all, only if GSK want to.
montyhedge
12/2/2018
13:07
badtime - bedtime?
tradermichael
12/2/2018
12:31
Moody says,"GSK could potentially be on the hook to pay Novartis an estimated GBP8.6 billion in relation to their common consumer health joint venture."
abdullla
12/2/2018
12:23
If the bribery allegations take hold then this would be the 3rd time GSK has landed in this mess after being penalised twice already !
abdullla
12/2/2018
11:21
Direct Advair competition looks increasingly unlikely this year following three approval failures from wannabes. Stories about "worries over threat to Advair revenue" are frankly getting tedious. Advair revenues should have been slammed two years ago if you listened to the "experts" and yet here we are nibbling into 2018 and still Advair going strong.

And even if you were to ignore all that, it is already clear that the new Resp portfolio is already more than making up for declining Advair income.

Similarly competition with Gilead is hardly a surprise given it is the market leader and while their new treatment has some pros over GSK offering in the near-term. However as GSK point out, VIIV's lower toxicity product, Juluca, has the potential to really dominate the market and very possibly allow GSK to take the top spot longer term.

romeike
12/2/2018
10:46
2ndly the New bribery allegations are not helping the share price to grow either!
abdullla
12/2/2018
10:11
Thats called ex dividend
ianood
12/2/2018
10:06
GSK investors very wary of the oncoming 23p share price drop !
abdullla
12/2/2018
10:01
Every blue chip in ftse 100 is a ftse tracker,but its the hedgehogs how they manipulate the SP!
abdullla
12/2/2018
09:50
Well buy a FTSE tracker instead!
ianood
12/2/2018
09:26
Market up triple digits these barely moved.
tim 3
12/2/2018
09:14
GSK out of sync with the rise in ftse!
abdullla
10/2/2018
09:53
She maybe Monty, but that message is still be reached, the share price is off course being held back by the outcome of the Pfizer auction, the threat of generics, and the oncoming question over drug pricing in the US and elsewhere, and some internals going back to 2013. The issue of the dividend is neither going to disappear, for now it is safe, but I would say these will, along the overall market falls continue to act as headwinds. They look like a value trap, either way to be honest, I suppose in times of market uncertainty, healthcare companies and food retailers tend to be safe havens, the two things the consumer most values and do not compromise upon, time will tell!
wormhasturned
10/2/2018
09:08
Emma is outstanding seen her in interviews, figures talk for themselves, best CEO GSK as ever had.
montyhedge
09/2/2018
23:54
BIG SHOT OF THE WEEK: Glaxo boss Emma Walmsley's early aptitude for winning people over through well-researched analysis has set tone for much of her soaring career


article link:

philanderer
09/2/2018
20:05
I thought this was old news!
bilster1
09/2/2018
19:43
I would be very interested to know which drugs in China and the time period. Anyone know?
alphorn
09/2/2018
18:25
GlaxoSmithKline faces fresh probe over allegations it bribed doctors to prescribe its drugs

Read more:

philanderer
09/2/2018
17:02
It will be nice to see another thousand drop on the DOW !
abdullla
09/2/2018
14:17
16629 - well, except it isn't:


free stock charts from uk.advfn.com



yet...

imastu pidgitaswell
09/2/2018
13:35
'Kepler upgrades Glaxo, says worst-case scenario priced in
philanderer
09/2/2018
11:57
SP Now going down to pre results levels,meaning nothing to show for it ,meanwhile yanks to resume status quo position,another 3000 points to go !
abdullla
Chat Pages: Latest  676  675  674  673  672  671  670  669  668  667  666  665  Older

Your Recent History

Delayed Upgrade Clock